Objective To observe the clinical effect of medical ozone combined with Diammonium Glycyrrhizinate capsules in the treatment of chronic hepatitis B and liver fibrosis, in order to provide basis for clinical treatment of liver fibrosis in chronic hepatitis B. Methods Ninety-eight cases of chronic hepatitis B liver fibrosis patients in department of infectious disease of the Second Hospital of Qinhuangdao from June 2016 to 2017 June included as the object study,the patients were di-vided into control group (49 cases) and observation group (49 cases) according to random number table method. The Patients in the control group were treated with routine antiviral and hepatoprotective drugs. Observation group were treated with medical ozone combined with Diammonium Glycyrrhizinate capsules on the basis of control group. The clinical effects,liver fibrosis in-dexes and liver function indexes of two groups were compared. Results The total effective of observation group was signifi-cantly higher than the control group (χ2 =9. 075,P=0. 003). There was no significant difference in liver fibrosis serological markers (Ⅳ C,PCⅢ,LN and HA) and liver biochemical markers ( AST,ALT and Tbil) between the two groups before treat-ment (t=0. 016, t=0. 089, t=0. 049, t=0. 072, t=0. 105, t=0. 345, t=0. 049,P=0. 987, P=0. 930, P=0. 961, P=0. 942, P=0. 917, P=0. 731, P=0. 642). After treatment,the serum fibrosis markers ⅣC,PCⅢ,LN and HA and AST,ALT and Tbil in liver function in both groups were significantly improved ( control group: t=4. 999, t=3. 531, t=4. 303, t=2. 476, t=9. 420, t=9. 827, t=6. 792, all P= 0. 000;observation group:t=7. 690, t=6. 917, t=9. 278,t=7. 852, t=12. 294, t=13. 660, t=11. 141, all P=0. 000),and the observation group was better than the control group (t=3. 099, t=2. 960, t=4. 768, t=5. 479, t=4. 742, t=5. 279, t=4. 608, all P=0. 000). There was no significant difference in gastrointestinal reaction between the two groups(χ2 =0. 211,P=0. 646). Conclusion Medical ozone combined with Diammonium Glycyrrhizinate capsules on the treatment of chronic hepatitis B fibrosis has good curative effect,the patients had no serious gastrointestinal reaction with high safety,and serum markers of liver fibrosis and liver function biochemical inde-xes of patients were improved,they can effectively improve the quality of life in patients.%目的 观察医用臭氧自血回输联合甘草酸二胺(商品名:甘利欣胶囊)治疗慢性乙型病毒性肝炎纤维化的临床效果.方法 选取2016年6月—2017年6月秦皇岛市第二医院感染科收治慢性乙型病毒性肝炎肝纤维化患者98例作为研究对象,通过随机数字表法分为对照组(49例)和观察组(49例).对照组患者给予常规的抗病毒及保肝降酶药物等基础治疗,观察组患者在对照组基础治疗上加用医用臭氧联合甘利欣胶囊治疗.比较2组患者的临床治疗效果、肝纤维化指标以及肝功能指标,并记录不良反应发生情况.结果 观察组总有效率明显高于对照组(87.7%vs.61.22%,χ2=9.075,P=0.003).治疗前2组患者的肝纤维化血清学指标Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)、层黏连蛋白(LN)及透明质酸(HA)和肝功能生化指标天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)及总胆红素(TBil)比较差异无统计学意义(P>0.05);治疗后,2组患者的肝纤维化血清学指标Ⅳ-C、PCⅢ、LN及HA和肝功能生化指标AST、ALT及TBil均明显改善(t对照组=4.990、3.531、4.303、2.476、9.420、9.827、6.792,P均<0.01;t观察组=7.690、6.917、9.278、7.852、12.294、13.660、11.141,P均<0.01),且观察组优于对照组(t=3.099、2.960、4.768、5.479、4.742、5.279、4.608,P均<0.01).2组患者的胃肠道反应比较差异无统计学意义(χ2=0.211,P=0.646).结论 医用臭氧联合甘利欣胶囊治疗慢性乙型病毒性肝炎纤维化具有良好疗效,可有效改善患者的肝纤维化指标及肝功能生化指标,安全性较高.
展开▼
